DIY Investing Newsletter

Share this post

Gilead Sciences Business Quality Report (GILD)

diyinvestingstocks.substack.com

Gilead Sciences Business Quality Report (GILD)

Trey Henninger
Aug 29, 2022
∙ Paid
Share
Share this post

Gilead Sciences Business Quality Report (GILD)

diyinvestingstocks.substack.com

Gilead Sciences is a leading biopharmaceutical company. This Gilead Sciences Business Quality Report explains the Excellent Quality ranking that Gilead received under my quality ranking system. 

DIY Investing Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Basic Company Information

  • Company Name: Gilead Sciences, Inc.

  • Ticker: GILD

  • Quality Ranking: Excellent (5)

  • Primary Reason: Patent Protection

  • Size: Large-Cap

  • Last Updated: 06/15/2018

Key Points:

  1. Patent protection guarantees pricing power.

  2. The industry leader in HIV drugs.

  3. An industry leader in HCV drugs.

  4. Ongoing diversification in oncology, inflammation, and liver diseases.

  5. Ability to expand/protect product line via acquisition or internal research.

Gilead’s Business Quality Description:

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2023 Trey Henninger
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing